Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer

Journal of Urology

Volumn 156, Issue 3, 1996, Pages 1042-1049

  Elgamal, Abdel Aziz A ^a   Cornillie, Freddy J ^b   Van Poppel, Hendrik P ^b   Van De Voorde, Wim M ^b   Mccabe, Richard ^b   Baert, Luc V ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

diagnosis; prostate specific antigen; prostatic hypertrophy; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; ENZYME IMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; TUMOR VOLUME;

EID: 0029764376     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65696-9     Document Type: Article

References (32)

1. Estève, J., Kricker, A., Ferlay, J. and Parkin, D. M.: Facts and Figures of Cancer in the European Community. Lyon, France: International Agency for Research on Cancer, p. 1, 1993.
2. Boring, C. C., Squires, T. S., Tong, T. and Montgomery, S.: Cancer statistics, 1994. CA, 44: 7, 1994.
3. Walsh, P. C.: Radical retropubic prostatectomy. In: Campbell's Urology, 6th ed. Edited by P. C. Walsh, A. B. Retik, T. A. Stamey and E. D. Vaughan, Jr. Philadelphia: W. B. Saunders Co., vol. 3, chapt. 78, pp. 2865-2886, 1992.
4. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317: 909, 1987.
5. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A. and Andriole, G. L.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl. J. Med., 324: 1156, 1991.
6. Benson, M. C., Whang, I. S., Olsson, C. A., McMahon, D. J. and Cooner, W. H.: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol., 147: 817, 1992.
7. Catalona, W. J., Richie, J. P., de Kernion, J. B., Ahmann, F. R., Ratliff, T. L., Dalkin, B. L., Kavoussi, L. R., MacFarlane, M. T. and Southwick, P. C.: Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J. Urol., 152: 2031, 1994.
8. Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., Fozard, J. L. and Walsh, P. C.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J.A.M.A., 267: 2215, 1992.
9. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Lieber, M. M.: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. J.A.M.A., 270: 860, 1993.
10. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222, 1991.
11. Christensson, A., Björk, T., Nilsson, O., Dahlén, U., Matikainen, M., Cockett, A. T. K., Abrahamsson, P.-A. and Lilja, H.: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J. Urol., 150: 100, 1993.
12. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T-1C) prostate cancer. J.A.M.A., 271: 368, 1994.
13. Elgamal, A. A., Van de Voorde, W. M., Van Poppel, H. P., Lauweryns, J. M. and Baert, L. V.: Selective zonal distribution of tumor volume vs grade in T1c prostate cancer. J. Urol., part 2, 153: 484A, abstract 1024, 1995.
14. Ohori, M., Wheeler, T. M. and Scardino, P. T.: The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer, 74: 104, 1994.
15. Van de Voorde, W. M., Elgamal, A. A., Van Poppel, H. P., Verbeken, E. K., Baert, L. V. and Lauweryns, J. M.: Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer, 74: 3164, 1994.
16. Stenman, U. H. and Lilja, H.: Prostate-specific antigen reagent workshop (parts 1 and 2). Read at 23rd Meeting of the International Society for Oncodevelopmental Biology and Medicine, Montreal, Canada, September 10-13, 1995.
17. Gann, P. H., Hennekens, C. H. and Stampfer, M. J.: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J.A.M.A., 273: 289, 1995.
18. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.-L. and Emond, J.: Serum prostate specific antigen as pre-screening test for prostate cancer. J. Urol., part 2, 147: 846, 1992.
19. Littrup, P. J., Kane, R. A., Mettlin, C. J., Murphy, G. P., Lee, F., Toi, A., Badalament, R. and Babaian, R.: Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer, 74: 3146, 1994.
20. Nishiya, M., Miller, G. J., Lookner, D. H. and Crawford, E. D.: Prostate specific antigen density in patients with histologically proven prostate carcinoma. Cancer, 74: 3002, 1994.
21. Benson, M. C.: Prostate specific antigen. J. Urol., 152: 2046, 1994.
22. Brawer, M. K, Aramburu, E. A. G., Chen, G. L., Preston, S. D. and Ellis, W. J.: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J. Urol., 150: 369, 1993.
23. Cookson, M. S., Floyd, M. K., Ball, T. P., Jr., Miller, E. K. and Sarosdy, M. F.: The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J. Urol., 154: 1070, 1995.
24. Hanks, G. E., Pearson, J. D., Catalona, W. J., Linehan, M. W., Bagshaw, M. A., Tribukait, B., Lange, P. H., Adolfsson, J. and Paulson, D. F.: Discussion. J. Urol., part 2, 152: 1749, 1994.
25. 1-antichymotrypsin. Clin. Chem., 37: 1618, 1991.
26. 1-antichymotrypsin before diagnosis of prostate cancer. Lancet, 344: 1594, 1994.
27. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L. and Nadler, R. B.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J.A.M.A., 274: 1214, 1995.
28. Luderer, A. A., Chen, Y.-T., Soriano, T. F., Kramp, W. J., Carlson, G., Cuny, C., Sharp, T., Smith, W., Petteway, J., Brawer, M. K. and Thiel, R.: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology, 46: 187, 1995.
29. Elgamal, A. A., Cornillie, F., Van Poppel, H., McCabe, R., Gero, E. and Baert, L.: Interpretation of free/total (F/T) PSA determinations in routine clinical practice. Read at 23rd Meeting of the International Society for Oncodevelopmental Biology and Medicine, Montreal, Canada, September 10-13, 1995.
30. Oesterling, J. E., Jacobsen, S. J., Klee, G. G., Pettersson, K., Piironen, T., Abrahamsson, P.-A., Stenman, U.-H., Dowell, B., Lövgren, T. and Lilja, H.: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol., 154: 1090, 1995.
31. Oesterling, J. E., Suman, V. J., Zincke, H. and Bostwick, D. G.: PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. N. Amer., 20: 687, 1993.
32. Scaletscky, R., Koch, M. O., Eckstein, C. W., Bicknell, S. L., Gray, G. F., Jr. and Smith, J. A., Jr.: Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. J. Urol., 152: 129, 1994.